Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Other
Mirtazapine is a tetracyclic antidepressant (TeCA) used primarily for Major Depressive Disorder. It functions as a noradrenergic and specific serotonergic antidepressant (NaSSA), offering a unique mechanism compared to traditional SSRIs.
Name
Mirtazapine
Raw Name
MIRTAZAPINE
Category
Other
Drug Count
3
Variant Count
124
Last Verified
February 17, 2026
RxCUI
283406, 283407, 283485, 311725, 311726, 314111, 476809, 211322, 211323, 752869, 752870, 752871
UNII
A051Q2099Q
About Mirtazapine
Mirtazapine is a tetracyclic antidepressant (TeCA) used primarily for Major Depressive Disorder. It functions as a noradrenergic and specific serotonergic antidepressant (NaSSA), offering a unique mechanism compared to traditional SSRIs.
Detailed information about Mirtazapine
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Mirtazapine.
Mirtazapine is a potent, second-generation antidepressant medication that belongs to a unique pharmacological class known as noradrenergic and specific serotonergic antidepressants (NaSSAs). Unlike the more commonly prescribed Selective Serotonin Reuptake Inhibitors (SSRIs) or Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), mirtazapine does not primarily work by inhibiting the reuptake of neurotransmitters. Instead, it acts as an antagonist at specific presynaptic and postsynaptic receptors to enhance neurotransmission.
Originally approved by the U.S. Food and Drug Administration (FDA) in 1996 under the brand name Remeron, mirtazapine has become a cornerstone in the treatment of Major Depressive Disorder (MDD), particularly in patients who suffer from comorbid insomnia or significant weight loss. Because it lacks the typical serotonergic side effects—such as nausea, agitation, and sexual dysfunction—that often plague SSRI therapy, it is frequently utilized as a first-line or second-line treatment option. In clinical practice, healthcare providers may also prescribe mirtazapine for various off-label conditions, including generalized anxiety disorder, post-traumatic stress disorder (PTSD), and chronic tension-type headaches, although its primary indication remains clinical depression.
The mechanism of action for mirtazapine is sophisticated and multi-faceted. At the molecular level, mirtazapine acts as an antagonist at central presynaptic alpha-2 adrenergic inhibitory autoreceptors and heteroreceptors. By blocking these receptors, the medication prevents the 'negative feedback' loop that usually limits the release of norepinephrine and serotonin. Consequently, there is an increase in central noradrenergic and serotonergic neurotransmission.
What sets mirtazapine apart is its 'specificity.' While it increases serotonin levels, it simultaneously blocks 5-HT2 and 5-HT3 receptors. By blocking the 5-HT2 receptor, mirtazapine helps prevent the anxiety, agitation, and sexual dysfunction often seen with other antidepressants. By blocking the 5-HT3 receptor, it effectively prevents nausea and gastrointestinal distress. The antidepressant effects are believed to be mediated through the enhancement of 5-HT1A-mediated neurotransmission. Additionally, mirtazapine is a very potent antagonist of Histamine (H1) receptors, which accounts for its significant sedative properties and its tendency to cause weight gain.
Understanding how the body processes mirtazapine is essential for optimizing therapy and minimizing adverse effects.
The FDA has officially approved mirtazapine for the treatment of Major Depressive Disorder (MDD) in adults. In clinical trials, it has demonstrated efficacy comparable to tricyclic antidepressants and SSRIs, often showing a faster onset of action regarding sleep and appetite improvements.
Off-label uses (uses not specifically approved by the FDA but supported by clinical evidence) include:
Mirtazapine is available in several oral formulations to accommodate different patient needs:
> Important: Only your healthcare provider can determine if Mirtazapine is right for your specific condition. The choice of formulation and dosage must be individualized based on your clinical presentation and medical history.
For the treatment of Major Depressive Disorder (MDD), the standard starting dose of mirtazapine is typically 15 mg once daily. Because of its sedative properties, healthcare providers almost universally recommend taking the dose in the evening, shortly before bedtime.
If the patient does not respond sufficiently to the 15 mg dose, the healthcare provider may increase the dosage in increments. The effective therapeutic range is generally considered to be between 15 mg and 45 mg per day. Dosage adjustments should typically occur at intervals of no less than one to two weeks to allow the full therapeutic response of the previous dose to be evaluated. While some clinical studies have explored doses up to 60 mg, the FDA-approved maximum dose is 45 mg per day.
Mirtazapine is NOT currently FDA-approved for use in pediatric patients (children and adolescents under the age of 18). Clinical trials have not established the safety and efficacy of mirtazapine in this population. Furthermore, like all antidepressants, mirtazapine carries a risk of increased suicidal thinking and behavior in children and young adults, necessitating extreme caution if a provider chooses to use it off-label in this group.
In patients with moderate to severe renal impairment (creatinine clearance < 40 mL/min), the clearance of mirtazapine is reduced by approximately 30% to 50%. Consequently, healthcare providers will typically start at the lowest possible dose and titrate upward very slowly, monitoring closely for adverse effects.
Because mirtazapine is extensively metabolized by the liver, patients with hepatic impairment (liver disease) show a reduction in clearance of about 30%. Dose reductions and careful monitoring are necessary in this population to prevent drug accumulation and toxicity.
Elderly patients often exhibit decreased renal and hepatic function, as well as increased sensitivity to the sedative and orthostatic (blood pressure dropping upon standing) effects of the drug. Lower starting doses and slower titration schedules are standard for patients over the age of 65.
If you miss a dose of mirtazapine, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Never 'double up' or take two doses at once to make up for a missed one, as this significantly increases the risk of over-sedation and other side effects.
Signs of a mirtazapine overdose may include severe drowsiness, disorientation, memory loss, and a rapid heart rate (tachycardia). In severe cases, respiratory depression or cardiac arrhythmias may occur. If an overdose is suspected, contact your local poison control center or seek emergency medical attention immediately. Treatment is generally supportive, focusing on maintaining the airway and monitoring cardiac function.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose, skip doses, or stop taking the medication without medical guidance, as this can lead to a relapse of symptoms or withdrawal effects.
Mirtazapine is generally well-tolerated, but its unique receptor profile leads to several very common side effects. Most patients will experience at least one of the following:
> Warning: Stop taking Mirtazapine and call your doctor immediately if you experience any of these serious symptoms:
With prolonged use, the most significant concern is the metabolic impact. Patients may experience long-term elevations in cholesterol and triglycerides. Regular monitoring of weight and lipid profiles is recommended. Additionally, while mirtazapine does not typically cause the sexual dysfunction seen with SSRIs, long-term use should still be monitored for any changes in libido or sexual function. There is also a risk of 'discontinuation syndrome' if the medication is stopped abruptly after long-term use, involving symptoms like anxiety, dizziness, and nausea.
Suicidality and Antidepressant Drugs: The FDA has issued a Black Box Warning for mirtazapine. Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults (ages 18-24) in short-term studies. Patients of all ages who are started on mirtazapine should be monitored closely for worsening of depression, suicidal thoughts, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber.
Report any unusual symptoms to your healthcare provider immediately. Do not wait for your next scheduled appointment if you feel your condition is worsening.
Mirtazapine is a powerful psychiatric medication that requires careful medical supervision. It is not a 'quick fix' for sadness and must be used as part of a comprehensive treatment plan. Patients should be aware that it may take several weeks (typically 2 to 4 weeks) before the full antidepressant effects are felt, although improvements in sleep and appetite may occur sooner.
Full FDA Text Summary: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of mirtazapine or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior.
Your healthcare provider may require the following tests during treatment:
Because mirtazapine causes significant somnolence (drowsiness) and can impair judgment and motor skills, you should not drive or operate heavy machinery until you are certain how the medication affects you. This impairment is often most severe during the first few days of treatment or after a dose increase.
Alcohol should be strictly avoided while taking mirtazapine. Alcohol significantly increases the sedative effects of the drug, leading to dangerous levels of impairment, respiratory depression, and an increased risk of accidents.
Do not stop taking mirtazapine abruptly. Abrupt cessation can lead to withdrawal symptoms, including nausea, dizziness, anxiety, and agitation. Your doctor will provide a tapering schedule to gradually reduce the dose over several weeks.
> Important: Discuss all your medical conditions, including any history of heart, liver, or kidney disease, with your healthcare provider before starting Mirtazapine.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete list is vital for preventing dangerous interactions.
There are specific scenarios where mirtazapine must NEVER be used because the risks far outweigh any potential benefits:
These are conditions where the healthcare provider must perform a careful risk-benefit analysis and monitor the patient very closely:
While mirtazapine is chemically unique (a tetracyclic), patients who have had severe reactions to other tetracyclic antidepressants (like maprotiline) should be monitored for potential cross-sensitivity, although this is rare. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should avoid the standard tablets as they contain lactose.
> Important: Your healthcare provider will evaluate your complete medical history, including any underlying physical or mental health conditions, before prescribing Mirtazapine.
Mirtazapine was previously classified as FDA Pregnancy Category C. This means that animal studies have shown an adverse effect on the fetus, but there are no adequate and well-controlled studies in humans.
Data indicates that mirtazapine is excreted into human breast milk in very small amounts. The relative infant dose is estimated to be less than 2% of the mother's weight-adjusted dose. While this is considered low, the long-term effects on a nursing infant's developing nervous system are unknown. If a mother takes mirtazapine while breastfeeding, the infant should be monitored for excessive sedation, poor feeding, or inadequate weight gain.
As previously stated, mirtazapine is not approved for use in children or adolescents. The primary concern is the increased risk of suicidal ideation. If used off-label for conditions like severe insomnia or refractory depression in youth, it must be done under the strict guidance of a child psychiatrist with frequent monitoring.
Elderly patients (age 65+) are at a higher risk for several mirtazapine-related complications:
In patients with a GFR (Glomerular Filtration Rate) below 40 mL/min, the clearance of mirtazapine is significantly impaired. This leads to higher plasma concentrations and a longer half-life. Physicians typically reduce the starting dose to 7.5 mg and titrate with extreme caution. Mirtazapine is not effectively removed by hemodialysis.
In patients with impaired liver function (Child-Pugh Class A, B, or C), the clearance of mirtazapine is reduced by approximately 30%. Because the liver is the primary site of metabolism, these patients are at a higher risk for drug accumulation. Regular liver function monitoring is recommended.
> Important: Special populations require individualized medical assessment and often necessitate a 'start low, go slow' approach to dosing.
Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA). Its primary mechanism involves the antagonism of central presynaptic alpha-2 adrenergic inhibitory autoreceptors and heteroreceptors. This blockade results in an increase in the release of both norepinephrine and serotonin (5-HT) into the synaptic cleft.
Furthermore, mirtazapine acts as a potent antagonist at 5-HT2 and 5-HT3 receptors. By blocking 5-HT2 receptors, it prevents the anxiety and sexual dysfunction associated with non-specific serotonin stimulation. By blocking 5-HT3 receptors, it prevents nausea. The net result is an enhancement of 5-HT1A-mediated neurotransmission, which provides the antidepressant effect. It also has a very high affinity for H1 histamine receptors, which explains its sedative and orexigenic (appetite-stimulating) effects.
The dose-response relationship for mirtazapine is well-established for depression within the 15-45 mg range. The onset of therapeutic effect for mood usually takes 2-4 weeks, though the sedative effect is immediate (within 1-2 hours of the first dose). Tolerance to the sedative effects may develop over several weeks, but the antidepressant effects generally persist with long-term use.
| Parameter | Value |
|---|---|
| Bioavailability | ~50% |
| Protein Binding | ~85% |
| Half-life | 20-40 hours |
| Tmax | ~2 hours |
| Metabolism | Hepatic (CYP2D6, CYP1A2, CYP3A4) |
| Excretion | Renal 75%, Fecal 15% |
Mirtazapine is a tetracyclic antidepressant. While it shares some structural similarities with tricyclic antidepressants (TCAs), its side effect profile and mechanism are distinct. It is the only NaSSA currently available in many markets, making it a unique tool in the psychiatric pharmacopeia.
Medications containing this ingredient
Common questions about Mirtazapine
Mirtazapine is primarily used to treat Major Depressive Disorder (MDD) in adults. Because of its unique mechanism, it is often chosen for patients who also struggle with insomnia or significant weight loss, as it promotes sleep and increases appetite. Healthcare providers may also use it 'off-label' to treat conditions like generalized anxiety disorder, PTSD, and certain types of chronic pain or headaches. It is particularly valued in patients who cannot tolerate the sexual side effects or nausea commonly caused by SSRIs. Only a doctor can determine if mirtazapine is the appropriate treatment for your specific mental health needs.
The most common side effects of mirtazapine include significant drowsiness (somnolence), increased appetite, and weight gain. Many patients also report having a dry mouth and experiencing constipation. Drowsiness is often most severe when first starting the medication or when taking lower doses, such as 15 mg. Weight gain is a very frequent reason patients stop taking the drug, as it can be substantial over several months. Most of these side effects are manageable, but you should discuss them with your doctor if they become bothersome or interfere with your daily life.
No, you should strictly avoid drinking alcohol while taking mirtazapine. Alcohol significantly increases the sedative effects of the medication, which can lead to extreme drowsiness, impaired coordination, and a higher risk of accidents. Combining the two can also lead to more severe respiratory depression and can worsen the underlying symptoms of depression or anxiety. Your ability to drive or operate machinery will be dangerously compromised if you mix alcohol with this drug. Always consult your healthcare provider about lifestyle choices while on psychiatric medication.
Mirtazapine should only be used during pregnancy if the potential benefits to the mother outweigh the potential risks to the developing fetus. There are no large-scale, definitive studies in humans to prove it is completely safe, although it is not currently linked to major birth defects. Some infants exposed to antidepressants late in pregnancy may experience temporary withdrawal symptoms or breathing difficulties after birth. It is crucial to have a detailed discussion with your obstetrician and psychiatrist to balance the risks of the medication against the risks of untreated depression. Never stop taking your medication during pregnancy without medical supervision.
While mirtazapine can help improve sleep and appetite within the first few days of treatment, its antidepressant effects usually take longer to manifest. Most patients begin to feel a significant improvement in their mood and interest in activities after 2 to 4 weeks of consistent use. The full therapeutic benefit may not be reached until you have been on an effective dose for 6 to 8 weeks. It is important to continue taking the medication as prescribed, even if you do not feel better right away. If you don't notice any improvement after 4 weeks, contact your doctor to discuss a possible dose adjustment.
You should never stop taking mirtazapine suddenly, as this can lead to 'discontinuation syndrome.' Symptoms of stopping too quickly include nausea, dizziness, anxiety, agitation, and vivid dreams. Furthermore, stopping the medication abruptly increases the risk that your depression or anxiety symptoms will return quickly. If you and your doctor decide to stop the medication, they will provide you with a tapering schedule to slowly reduce the dose over several weeks. This gradual reduction helps your brain adjust and minimizes uncomfortable withdrawal symptoms.
If you miss a dose of mirtazapine, take it as soon as you remember, provided it is not too close to your next scheduled dose. If it is almost time for your next dose (for example, if you remember the next morning), simply skip the missed dose and continue with your regular schedule at bedtime. Do not take two doses at once to make up for a missed one, as this will significantly increase the risk of excessive sedation and other side effects. Consistency is key to the effectiveness of the treatment, so try to take it at the same time every night.
Yes, weight gain is one of the most common and significant side effects of mirtazapine. The drug acts on histamine and serotonin receptors that regulate hunger, often leading to a marked increase in appetite and specific cravings for carbohydrates. In clinical trials, a significant percentage of patients gained 7% or more of their body weight during treatment. This effect is often dose-dependent, though even low doses can cause it. If you are concerned about weight gain, talk to your doctor about monitoring your weight and implementing dietary or exercise strategies while on the medication.
Mirtazapine can interact with several other medications, some of which are dangerous. It must never be taken with MAOIs, and it should be used very cautiously with other serotonergic drugs like SSRIs or triptans due to the risk of serotonin syndrome. It also interacts with CNS depressants like benzodiazepines and sleep aids, which can cause extreme drowsiness. Some medications that affect liver enzymes, like certain antibiotics or anti-seizure drugs, can change the levels of mirtazapine in your blood. Always provide your doctor and pharmacist with a full list of all prescriptions, over-the-counter drugs, and supplements you are taking.
Yes, mirtazapine is widely available as a generic medication in both standard tablet and orally disintegrating tablet (ODT) forms. Generic versions are typically much more affordable than the original brand-name drug (Remeron) and are required by the FDA to have the same active ingredient, strength, dosage form, and route of administration. Most insurance plans cover the generic version of mirtazapine. If you have concerns about the cost of your medication or the switch from a brand to a generic, discuss them with your pharmacist or healthcare provider.